Paul J Clancy
CIK 1409601 · EVP, Chief Financial Officer · last filed 2026-10-02
Paul J Clancy is an EVP, Chief Financial Officer who has filed 136 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider was granted $24.6K of INCY on Oct 2, 2026. Across all open-market trades the lifetime net is −$50.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.6M across reported positions. 56 SEC filings were submitted jointly with BIOGEN INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WILMINGTON, DE 19803
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 25,838 | $113.07 | $2.92M | -$1.42M | 45 | 2026-10-02 |
| SION | Director | — | $3.89 | — | $0 | 2 | 2026-06-18 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 0 | $104.91 | $0 | $0 | 8 | 2026-03-23 |
| XLO | Director | — | $8.55 | — | $0 | 5 | 2025-06-12 |
| AGIO | Director | 6,549 | $31.32 | $205.1K | $0 | 12 | 2022-06-23 |
| BIIB | Executive VP and CFO | 10,813 | $232.65 | $2.52M | -$48.55M | 55 | 2017-04-27 |
Recent Filings
136 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-02 | INCY | Grant (A) | +203 | $24.6K | EDGAR |
| 2026-07-02 | INCY | Grant (A) | +252 | $28.6K | EDGAR |
| 2026-06-18 | SION | Grant (A) | — | $0 | EDGAR |
| 2026-06-10 | INCY | Grant (A) | +1,642 | $0 | EDGAR |
| 2026-05-21 | INCY | Mixed | — | -$156.0K | EDGAR |
| 2026-05-19 | INCY | Notice (144) | −15,000 | -$1.42M | EDGAR |
| 2026-04-02 | INCY | Grant (A) | +265 | $24.9K | EDGAR |
| 2026-03-23 | EXACT SCIENCES CORP (EXAS) Delisted | Disp (D) | −26,038 | $0 | EDGAR |
| 2026-01-05 | INCY | Grant (A) | +241 | $23.8K | EDGAR |
| 2025-10-02 | INCY | Grant (A) | +285 | $24.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.